Danish cannabis company StenoCare has quarantined five batches of cannabis oil produced by CannTrust following Health Canada’s ruling that the greenhouse where the cannabis used to produce the oil was cultivated was non-compliant, the company announced today.
Initially, StenoCare had quarantined just one batch on Wednesday, but upped the quarantine following “new information” from the Canadian firm.
“The most likely consequence from this new situation is that there will be a temporary shortage of medical cannabis products to the Danish market.” – StenoCare, in a statement, via Reuters
StenoCare did not indicate how much of the oil products had reached consumers but said all products were tested by a third-party and met health standards required for medical cannabis products.
The Danish company notes that the quarantine “will have negative financial consequences … irrespective of the fact that CannTrust is contractually committed to deliver fully licensed and approved products” to the company for medical cannabis patients.
“Stenocare deals with any issues relating to quality and approval of products with the greatest level of attention and seriousness. Stenocare’s first priority is and will always be patient safety,” the company said in a Wednesday statement. “All products that are sourced from CannTrust have been tested for all the required quality standards, and independent third-party Lab analysis has documented this prior to receiving the products into the Stenocare warehouse in Denmark. Therefore, this matter does not point to any negative consequences to patient safety.”
Health Canada is currently performing quality inspections at CannTrust’s Pelham, Ontario facility; the results are expected within 12 business days.